Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.53 |
| ▸ | BAD | Q92934 | 1/20 | 0.53 |
| ▸ | CHRNE | Q04844 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 2/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 3/20 | 0.38 |
| ▸ | RXRB | P28702 | 3/20 | 0.38 |
| ▸ | RXRG | P48443 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8872355 | 0.98 | BCL2L1 (0.55) | BCL2L1BADCHRNETBXA2RALDH1A1 | |
| SCHEMBL19354043 | 0.94 | BCL2L1 (0.50) | BCL2L1BADCHRNETBXA2RALDH1A1 | |
| SCHEMBL30620247 | 0.94 | BCL2L1 (0.50) | BCL2L1BADCHRNETBXA2RALDH1A1 | |
| SCHEMBL7818234 | 0.85 | BCL2L1 (0.50) | BCL2L1BADCHRNETBXA2RALDH1A1 | |
| SCHEMBL3886272 | 0.82 | BCL2L1 (0.52) | BCL2L1BADCHRNETBXA2RALDH1A1 | |
| SCHEMBL11000510 | 0.82 | PNMT (0.45) | BCL2L1BADCHRNEALDH1A1TSHR | |
| SCHEMBL9720039 | 0.81 | BCL2L1 (0.54) | BCL2L1BADTBXA2RALDH1A1TSHR | |
| SCHEMBL10602990 | 0.80 | PNMT (0.50) | BCL2L1BADTBXA2RALDH1A1TSHR | |
| SCHEMBL19249593 | 0.80 | BCL2L1 (0.48) | BCL2L1BADTBXA2RALDH1A1TSHR | |
| SCHEMBL11355027 | 0.79 | BCL2L1 (0.48) | BCL2L1BADCHRNETBXA2RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531613-B | Benzo-aliphatic ring-substituted alkylamine compound and application thereof | 华东理工大学 | 2021-02-05 | — | — | CN | disclosed |
| WO-2017132912-A1 | ALKYLAMINE WITH BENZOALICYCLIC SUBSTITUENT AND APPLICATION THEREOF | 华东理工大学 | 2017-08-10 | — | — | WO | disclosed |
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
| US-6133446-A | Heterocyclic compounds for the treatment of CNS and cardiovascular disorders | PHARMACIA & UPJOHN COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0737189-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | UPJOHN CO (US) | 1999-07-28 | — | — | EP | disclosed |
| US-5877317-A | Heterocyclic compounds for the treatment of CNS and cardiovascular disorders | PHARMACIA & UPJOHN COMPANY (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0737189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 1996-10-16 | — | — | EP | disclosed |
| WO-1995018118-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | THE UPJOHN COMPANY (US) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | BCL2L1 1662/4885BAD 3041/4885CHRNE 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.